share_log

Needham Reiterates Buy on Blueprint Medicines, Maintains $133 Price Target

Needham Reiterates Buy on Blueprint Medicines, Maintains $133 Price Target

Needham重申買入blueprint medicines,維持133美元的目標價格
Benzinga ·  10/30 07:50  · 評級/大行評級

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $133 price target.

Needham分析師Ami Fadia重申對blueprint medicines(納斯達克:BPMC)的買入評級,並維持目標股價133美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論